PHASE I EXPANSION STUDY OF MIRVETUXIMAB SORAVTANSINE, A FOLATE RECEPTOR ALPHA (FRa)-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH ENDOMETRIAL CANCER

Mapping Intimacies ◽

10.26226/morressier.59ba7298d462b80296ca210c ◽

2017 ◽

Author(s):

Lainie Martin

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Download Full-text

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Case Medical Research ◽

10.31525/ct1-nct04300556 ◽

2020 ◽

Author(s):

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Tumor Types ◽

Download Full-text

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdz250 ◽

2019 ◽

Vol 30 ◽

pp. v403 ◽

Author(s):

K. Moore ◽

A. Oza ◽

N. Colombo ◽

A. Oaknin ◽

G. Scambia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Phase Iii ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Phase Iii Study ◽

Download Full-text

Abstract 1770: Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors

10.1158/1538-7445.am2018-1770 ◽

2018 ◽

Author(s):

Caroline Mignard ◽

Coralie DURIX ◽

Katherine Rybinski ◽

Xin Cheng ◽

Keiji Furuuchi ◽

...

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Download Full-text

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia ◽

10.1016/j.neo.2016.11.002 ◽

2016 ◽

Vol 18 (12) ◽

pp. 775-784 ◽

Author(s):

Jose F. Ponte ◽

Olga Ab ◽

Leanne Lanieri ◽

Jenny Lee ◽

Jennifer Coccia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Standard Of Care ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Cancer Models ◽

Download Full-text

Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.11.066 ◽

2020 ◽

Vol 156 (3) ◽

pp. e15-e16

Author(s):

Kathleen G. Essel ◽

Lainie P. Martin ◽

David M. O’Malley ◽

Ursula Matulonis ◽

Jason A. Konner ◽

...

Keyword(s):

Ovarian Cancer ◽

Safety Profile ◽

Folate Receptor ◽

Recurrent Ovarian Cancer ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Download Full-text

Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

Annals of Oncology ◽

10.1093/annonc/mdz250.036 ◽

2019 ◽

Vol 30 ◽

pp. v419-v420

Author(s):

D. O'Malley ◽

D. Richardson ◽

I.B. Vergote ◽

L. Gilbert ◽

L.P. Martin ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Initial Results ◽

Download Full-text

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.085 ◽

2018 ◽

Vol 149 ◽

pp. 38 ◽

Author(s):

U.A. Matulonis ◽

K.N. Moore ◽

L.P. Martin ◽

I.B. Vergote ◽

C.M. Castro ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Download Full-text

Combination Regimens of Mirvetuximab Soravtansine, A Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, With Standard-Of-Care Agents Offer Promise for the Treatment of Ovarian Cancer

Health Care Current Reviews ◽

10.4172/2375-4273.1000195 ◽

2017 ◽

Vol 05 (02) ◽

Author(s):

Todd M Bauer

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Standard Of Care ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Combination Regimens ◽

Download Full-text

Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5518 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5518-5518 ◽

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

David M. O'Malley ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Phase I Trial ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Download Full-text

Preclinical evaluation of M-DGN549, a folate receptor alpha-targeting antibody–drug conjugate (ADC) with a DNA-alkylating payload

European Journal of Cancer ◽

10.1016/s0959-8049(16)33030-1 ◽

2016 ◽

Vol 69 ◽

pp. S145

Author(s):

Y. Setiady ◽

L. Lanieri ◽

O. Ab ◽

E. Maloney ◽

E. Hong ◽

...

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Preclinical Evaluation ◽

Receptor Alpha ◽

Drug Conjugate ◽

Download Full-text